Newnan
NEWNAN, Georgia, December 1 - CeloNova BioSciences, Inc., a provider of specialty surface treatments
for medical devices and of specialty implants, today announced that President
and Chief Executive Officer, Thomas A.
NEWNAN, Georgia, December 1 - CeloNova BioSciences, Inc., a provider of specialty surface treatments
for medical devices and of specialty implants, today announced that Barry
Katzen, MD, FACR, FACC, FSCAI, founder and medical director of Baptist
Cardiac & Vascular Institute in Miami, Florida, will discuss the CATANIA(TM)
Stent System with NanoThin Polyzene(R)-F at the Innovations in Cardiovascular
Interventions Conference to be held at the Hotel David InterContinental in
Tel Aviv, Israel, which will include new information about the stent's
coating, Polyzene(R)-F, and clinical outcomes in coronary, below-the-knee,
and neurovascular applications.
NEWNAN, Georgia -
In the news release, French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent, issued Oct.
NEWNAN, Georgia -
Physicians at more than 40 centers in France have joined a study of the CATANIA(TM) Coronary Stent with NanoThin Polyzene(R)-F manufactured by CeloNova BioSciences.
NEWNAN, Georgia -
CeloNova BioSciences today announced that the company is submitting to its European Notified Body a request for approval of its new, lime green, 2800 micron size Embozene(TM) Microsphere.
